Objective Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) and to derive diagnostic strategies that could reduce the need for liver biopsies. Design Individual patient data meta-analysis of studies evaluating LSM-VCTE against liver histology was conducted. FIB-4 and NFS were computed where possible. Sensitivity, specificity and area under the receiver operating curve (AUROC) were calculated. Biomarkers were assessed individually and in sequential combinations. Results Data were included from 37 primary studies (n=5735; 45% women; median age: 54 years; median body mass index: 30 kg/m2; 33% had type 2 diabetes; 30% had advanced fibrosis). AUROCs of individual LSM-VCTE, FIB-4 and NFS for advanced fibrosis were 0.85, 0.76 and 0.73. Sequential combination of FIB-4 cut-offs (<1.3; ≥2.67) followed by LSM-VCTE cut-offs (<8.0; ≥10.0 kPa) to rule-in or rule-out advanced fibrosis had sensitivity and specificity (95% CI) of 66% (63-68) and 86% (84-87) with 33% needing a biopsy to establish a final diagnosis. FIB-4 cut-offs (<1.3; ≥3.48) followed by LSM cut-offs (<8.0; ≥20.0 kPa) to rule out advanced fibrosis or rule in cirrhosis had a sensitivity of 38% (37-39) and specificity of 90% (89-91) with 19% needing biopsy. Conclusion Sequential combinations of markers with a lower cut-off to rule-out advanced fibrosis and a higher cut-off to rule-in cirrhosis can reduce the need for liver biopsies.

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis

Bugianesi E.;Bugianesi E.;Rosso C.;Armandi A.;
2021

Abstract

Objective Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) and to derive diagnostic strategies that could reduce the need for liver biopsies. Design Individual patient data meta-analysis of studies evaluating LSM-VCTE against liver histology was conducted. FIB-4 and NFS were computed where possible. Sensitivity, specificity and area under the receiver operating curve (AUROC) were calculated. Biomarkers were assessed individually and in sequential combinations. Results Data were included from 37 primary studies (n=5735; 45% women; median age: 54 years; median body mass index: 30 kg/m2; 33% had type 2 diabetes; 30% had advanced fibrosis). AUROCs of individual LSM-VCTE, FIB-4 and NFS for advanced fibrosis were 0.85, 0.76 and 0.73. Sequential combination of FIB-4 cut-offs (<1.3; ≥2.67) followed by LSM-VCTE cut-offs (<8.0; ≥10.0 kPa) to rule-in or rule-out advanced fibrosis had sensitivity and specificity (95% CI) of 66% (63-68) and 86% (84-87) with 33% needing a biopsy to establish a final diagnosis. FIB-4 cut-offs (<1.3; ≥3.48) followed by LSM cut-offs (<8.0; ≥20.0 kPa) to rule out advanced fibrosis or rule in cirrhosis had a sensitivity of 38% (37-39) and specificity of 90% (89-91) with 19% needing biopsy. Conclusion Sequential combinations of markers with a lower cut-off to rule-out advanced fibrosis and a higher cut-off to rule-in cirrhosis can reduce the need for liver biopsies.
GUT
324243
324256
biostatistics; clinical decision making; fatty liver; hepatic fibrosis
Mozes F.E.; Lee J.A.; Selvaraj E.A.; Jayaswal A.N.A.; Trauner M.; Boursier J.; Fournier C.; Staufer K.; Stauber R.E.; Bugianesi E.; Younes R.; Gaia S.; Lupsor-Platon M.; Petta S.; Shima T.; Okanoue T.; Mahadeva S.; Chan W.-K.; Eddowes P.J.; Newsome P.N.; Wong V.W.-S.; de Ledinghen V.; Fan J.; Shen F.; Cobbold J.F.; Sumida Y.; Okajima A.; Schattenberg J.M.; Labenz C.; Kim W.; Lee M.S.; Wiegand J.; Karlas T.; Yilmaz Y.; Aithal G.P.; Palaniyappan N.; Cassinotto C.; Aggarwal S.; Garg H.; Ooi G.J.; Nakajima A.; Yoneda M.; Ziol M.; Barget N.; Geier A.; Tuthill T.; Brosnan M.J.; Anstee Q.M.; Neubauer S.; Harrison S.A.; Bossuyt P.M.; Pavlides M.; Anstee Q.; Daly A.; Johnson K.; Govaere O.; Cockell S.; Tiniakos D.; Bedossa P.; Oakley F.; Cordell H.; Day C.; Wonders K.; Bossuyt P.; Zafarmand H.; Vali Y.; Lee J.; Ratziu V.; Clement K.; Pais R.; Schuppan D.; Schattenberg J.; Schuppan D.; Schattenberg J.; Vidal-Puig T.; Vacca M.; Rodrigues-Cuenca S.; Allison M.; Kamzolas I.; Petsalaki E.; Oresic M.; Hyotylainen T.; McGlinchey A.; Mato J.M.; Millet O.; Dufour J.-F.; Berzigotti A.; Pavlides M.; Harrison S.; Neubauer S.; Cobbold J.; Mozes F.; Akhtar S.; Banerjee R.; Kelly M.; Shumbayawonda E.; Dennis A.; Erpicum C.; Graham M.; Romero-Gomez M.; Gomez-Gonzalez E.; Ampuero J.; Castell J.; Gallego-Duran R.; Fernandez I.; Montero-Vallejo R.; Karsdal M.; Erhardtsen E.; Rasmussen D.; Leeming D.J.; Fisker M.J.; Sinisi A.; Musa K.; Betsou F.; Sandt E.; Tonini M.; Bugianesi E.; Rosso C.; Armandi A.; Marra F.; Gastaldelli A.; Svegliati G.; Boursier J.; Francque S.; Vonghia L.; Ekstedt M.; Kechagias S.; Yki-Jarvinen H.; Porthan K.; van Mil S.; Papatheodoridis G.; Cortez-Pinto H.; Valenti L.; Petta S.; Miele L.; Geier A.; Trautwein C.; Aithal G.; Hockings P.; Newsome P.; Wenn D.; Rodrigues C.M.P.; Chaumat P.; Hanf R.; Trylesinski A.; Ortiz P.; Duffin K.; Brosnan J.; Tuthill T.; McLeod E.; Ertle J.; Younes R.; Ostroff R.; Alexander L.; Kjaer M.S.; Mikkelsen L.F.; Balp M.-M.; Brass C.; Jennings L.; Martic M.; Loeffler J.; Hanauer G.; Shankar S.; Fournier C.; Pepin K.; Ehman R.; Myers J.; Ho G.; Torstenson R.; Myers R.; Doward L.
File in questo prodotto:
File Dimensione Formato  
Mozes 2021.doc

Accesso riservato

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 1.48 MB
Formato Microsoft Word
1.48 MB Microsoft Word   Visualizza/Apri   Richiedi una copia
Mozes 2021.pdf

Accesso aperto

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 1.27 MB
Formato Adobe PDF
1.27 MB Adobe PDF Visualizza/Apri
1006.full.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 1.57 MB
Formato Adobe PDF
1.57 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1805145
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 22
  • ???jsp.display-item.citation.isi??? ND
social impact